Group B Streptococcus (GBS) is a leading cause of neonatal sepsis in developed countries. Its burden in the developing world is less clear. Studies reporting neonatal GBS disease incidence from developing countries were identified from 5 literature databases. Studies were assessed with respect to case finding and culture methods. Only 20 studies were identified. The GBS incidence ranged 0-3.06 per 1000 live births with variation within and between geographic regions. All but 1 study identified GBS cases within a hospital setting, despite the potential for births in the community. Possible case under-ascertainment was only discussed in 2 studies. A higher GBS incidence was reported when using automated culture methods. Prospective, population-based surveillance is urgently needed in developing countries to provide an accurate assessment of the neonatal GBS disease burden. This will be crucial for the design of interventions, including novel vaccines, and the understanding of their potential to impact mortality from neonatal sepsis.
An estimated 7.2 million deaths in children aged <5 years occurred in 2011 [1] , 40% of these within the first month of life. Severe infection contributes to approximately one-third of neonatal deaths in developing countries, which is where neonatal mortality is concentrated [1, 2] . Knowledge of the most common etiological agents causing neonatal infection is essential to develop effective strategies to prevent and treat serious neonatal infections and support progress toward Millennium Development Goal 4, which targets mortality in children aged <5 years.
In the 1970s, group B Streptococcus (GBS) was first described as a leading cause of neonatal sepsis in the United States [3] . This has been confirmed in more recent US, European, and Australasian studies [4] [5] [6] [7] . Neonatal GBS is divided into early-onset disease (EOD), occurring 0-6 days after birth, and late-onset disease (LOD), occurring 7-89 days after birth [8] . While EOD is primarily vertically transmitted in mothers colonized with GBS, and at least 80% of cases occur within the first 48 hours of life [9] , LOD is acquired in a healthcare or community setting. Many developed countries have introduced intrapartum antibiotic prophylaxis (IAP) in mothers colonized by GBS or with an increased risk of neonatal sepsis [6, 10, 11] . Although IAP programs have been associated with reductions in EOD incidence, disease has not been eliminated, mainly because vaginal colonization is a dynamic state. The incidence of LOD remains unaffected by IAP [11] .
Although the epidemiology of GBS in the developed world is well documented, its contribution to the burden of neonatal infection in the developing world has proved more difficult to assess. Group B Streptococcus has been reported as the predominant cause of neonatal sepsis in southern Africa and Kenya [12] [13] [14] [15] , but Asian studies have reported a lower incidence [16] [17] [18] . Differential exposure to GBS, with variation in maternal colonization rates, has been proposed to explain this variation. However, colonization studies from developing countries, based upon validated isolation and culture methods, have reported only limited variation in maternal GBS colonization rates (14%-22%) [19] .
We hypothesize that GBS incidence estimates from developing countries are confounded by case under-ascertainment due to barriers to accessing healthcare and challenges in equipping and maintaining diagnostic laboratories. This review aims to describe GBS incidence with respect to key methodological parameters-namely, case ascertainment, culture methods for GBS isolation and identification, and IAP use. The potential for these variables to contribute to differences in neonatal GBS incidence is discussed.
METHODS
Searches of the PubMed, Embase, Pascal, Cochrane Collaboration, and African Index Medicus databases were completed to identify studies of GBS incidence published until August 2011. No lower publication date limit was set. Relevant studies were identified using combinations of medical subject headings and text terms as follows: ("infant, newborn" OR "infant" OR "neonate") AND ("sepsis" OR "septicemia" OR "bacteremia" OR "meningitis" OR "pneumonia" OR "Streptococcus agalactiae" OR "group B Streptococcus"). The titles and abstracts of English-language references, as well as full texts where needed, were screened. Searches were supplemented by reviewing, without language restrictions, the bibliographies of identified studies. Searches, article reviews, application of inclusion/exclusion criteria, and data extraction were completed independently by 2 authors (A. F. D. and M. C.).
Studies were included if they met the following five criteria: (1) reported GBS incidence or raw data allowing the calculation of GBS incidence; (2) reported GBS incidence among infants aged <90 days; (3) included a clear description of GBS case identification in the study population and details of that population (case ascertainment); (4) included a clear description of the culture methods used to isolate and identify pathogens; and (5) were completed in developing countries defined as a low-, lower middle-, or upper middle-income country by the World Bank [20] .
The GBS incidence (overall, EOD, and LOD) was extracted from studies meeting inclusion criteria. Data on the distribution of sepsis-causing organisms in neonatal study populations were extracted if available. Incidence estimates are discussed with respect to GBS case ascertainment, culture methodology for GBS isolation and identification, and IAP use in the study population.
Statistical Methods
Neonatal GBS incidence rates were descriptively reported. Individual study data were not pooled. In cases in which incidence rates were calculated using reported raw data, incidence was estimated as:
Number of GBS cases Total number of live births in the study population Â 1000 livebirths
The number of live births could represent hospital or community-based estimates.
RESULTS

Characteristics of Studies
Initial literature searches identified 72 studies, 54 of which reported neonatal GBS incidence; however, only 20 studies provided sufficient detail of case ascertainment and culture methodology to be included in the review (Figure 1 ). There were 8 studies from sub-Saharan Africa, 2 from the Middle East, 5 from South Asia, 2 from Southeast Asia, and 3 from Latin America (Figure 2 ). No studies were identified from Eastern Europe. Studies with insufficient methodological detail were excluded from analysis. Although this excluded studies from Ethiopia, Jamaica, Panama, Thailand, Sri Lanka, and Libya, independent studies from similar geographic regions were available for review, preventing a distorted geographic representation in the overall analysis.
The final 20 studies captured age groups ranging from neonates to infants aged <90 days. Because data from published studies consistently indicated the preponderance of GBS disease occurs in the neonatal period (ie, first 28 days of life), the overall GBS incidence was based on studies with case capture limited to the neonatal period as well as those targeting the first 3 months of life (Table 1) .
Incidence and Case Fatality of Neonatal GBS
The overall incidence of GBS ranged 0-3.06 per 1000 live births (Table 1) . Differences in incidence were observed both between and within geographic regions. Variation was greatest across sub-Saharan Africa, with studies from Nigeria and the Gambia reporting lower incidence rates (0-0.17 per 1000 live births [21, 22] ) than studies from southern Africa (1.80-3.06 per 1000 live births [12-13, 23, 24] ). Variation was evident across studies from Latin America (0.39-1.15 per 1000 live births [25] [26] [27] ), whereas studies from Asia and the Middle East reported a lower GBS incidence (0-0.26 per 1000 live births [16] [17] [18] [28] [29] [30] [31] [32] [33] ). Reported case fatality rates (median, 20%; range, 10%-60%) also varied within and between geographic regions.
The 20 studies identified GBS cases among patients with suspected bacteremia, septicemia, or sepsis. Two additional studies that met inclusion criteria identified GBS cases among infants presenting with meningitis alone [34, 35] . Because only a proportion of neonatal GBS presents as meningitis, GBS incidence is likely to be underestimated using this clinical presentation alone [8] ; hence the 2 studies are presented separately in Supplementary Table 1 .
Incidence of EOD and LOD
The incidence of EOD and LOD GBS is presented in Table 2 , although comparisons are complicated by the use of different EOD and LOD definitions. An EOD definition of presentation <7 days after birth was most common (8 studies; [12-14, 16, 22, 25, 27, 33] ), with a reported EOD incidence of 0-2.06 per 1000 live births. The percentage of GBS cases presenting as EOD ranged 0%-100% (median, 59.1%).
Irrespective of the EOD and LOD definition, 6 of the 13 studies that differentiated EOD and LOD cases failed to report any cases of LOD [16-18, 28, 30, 31] . In contrast, Mulholland et al [22] failed to capture any EOD cases but identified 2 GBS cases in infants aged 7 and 11 days.
Where available (12 studies), data were extracted on age at disease onset, given the expectation that most cases (at least 80%) present within the first 48 hours of life [6, 9] (Table 2 ). All EOD cases from studies from India [17, 31] , Malaysia [18, 30] , and Brazil [25] presented within the first 48 hours after birth. Detailed distributions of the age at onset from southern African studies confirmed a predominance of GBS cases within the first days of life [12] [13] 23] .
Organisms Isolated
Fourteen studies reported the overall distribution of cultureconfirmed pathogens in the study population presenting with suspected bacteremia or sepsis (Table 3) . A lower reported GBS incidence was associated with a predominance of sepsis caused by Gram-negative bacteria (eg, Escherichia coli., Klebsiella spp., Acinetobacter spp.) and Staphylococcus aureus [16, 18, 21, 22, [28] [29] [30] [31] [32] [33] . Several studies reported the frequent isolation of coagulase-negative staphylococci (between 9% and 51% of isolates) [18, 29, 30] . 
GBS Case Ascertainment
All but 1 study identified GBS cases from hospital admissions for clinically suspected bacteremia, sepsis, septicemia, and/or meningitis (Table 1) . Only Darmstadt et al [16] attempted community-based case finding in addition to a hospital-based approach. Tertiary referral centers were represented in all but 3 studies [14, 15, 22] . Only studies from Kenya and Mozambique represented predominantly rural populations [15, 16] .
GBS cases were identified from an at-risk population of live births, which provided the denominator for GBS incidence calculations. Fifteen studies used hospital-born live birth estimates as the rate denominator, whereas 5 studies used community-based live birth estimates [13] [14] [15] [16] 22] .
Given the reliance upon hospital-born live birth denominators, data were extracted on the proportion of study population births occurring within the study-specific hospital centers. These data were discussed in only 2 studies: Gray et al estimated that 68% of births occurred in healthcare facilities in the Blantyre district [14] . Berkley et al [14] estimated that only 15% of births in the coastal Kenyan population occurred in the community hospital ascertaining bacteremia cases.
Culture Methodology
Thirteen studies, including all studies from South and Southeast Asia and the Middle East [16] [17] [18] [28] [29] [30] [31] [32] [33] , used manual culture methods to isolate and identify GBS, and 7 used automated methods, namely the BACTEC system. Neonatal GBS incidence rates were consistently higher among studies using automated culture methods (0.80-3.06 per 1000 live births automated vs 0-0.39 per 1000 live births manual). The studies from Brazil are important insofar that use of manual culture systems was again associated with a lower GBS incidence [25] [26] .
Additional details of the culture process, including site of isolation, blood volume, culture bottles, and contamination rates, were extracted. Of the 20 studies, 6 collected blood samples alone for culture [14-16, 18, 28, 32] and 14 collected both blood and cerebrospinal fluid (CSF) samples (with a median 21.4% of GBS isolates confirmed from CSF) [12-13, 17, 21-27, 29-31, 33] (Table 4) .
Additional culture process data proved scarce. Seven studies reported the blood volume extracted, which ranged 0.5-3.0 mL [14, 16, 18, 25, 26, 28, 32] , but only 2 studies reported on Figure 2 . Geographic distribution of studies of group B Streptococcus incidence in low-and middle-income countries. Abbreviation: OECD, Organization for Economic Cooperation and Development. culture bottles used: BACTEC pediatric for both [14] [15] . Contamination rates were available from only 3 studies, which estimated rates of 14.3%, 13%, and 3.2% from Kenya, Mozambique, and Bangladesh, respectively [15, 16] .
Antibiotic Use
Data on IAP, which directly affects the incidence of EOD, were rarely available. Cutland et al [24] reported that 10% of the South African study population was exposed to IAP. Gray et al [13] and Madhi et al [12] reported the use of riskbased IAP programs in Malawi and South Africa, respectively, but could not quantify exposure prevalence due to a lack of audit data.
DISCUSSION
Incidence and Case Fatality of Neonatal GBS
Twenty studies were identified from developing countries and reported an overall neonatal GBS incidence of 0-3.06 per 1000 live births. Variation in incidence was observed both within and between geographic regions, although lower incidence estimates were consistently reported from Asia and the Middle East. Within-region incidence variation was most evident in sub-Saharan Africa. Only 2 studies outside of Africa collected data after the year 2000, meaning the current epidemiological situation may not be represented for many regions. Case fatality rates were high (>10%) across all studies reporting GBS.
Within developed countries, vertical transmission is the primary mode of GBS neonatal infection, and in the absence of IAP, EOD predominates [6, 10] . Within this review, EOD predominated, although there was substantial variation in incidence. In the absence of GBS, Gram-negative bacteria and S. aureus, pathogens often considered to be postnatally acquired from the environment, predominated, something previously observed in studies of community-acquired neonatal infections [36] . Potential explanations include fundamental differences in disease epidemiology due to differences in maternal GBS colonization, strain virulence, or antibody levels, although previous reviews have reported insufficient variation in maternal GBS colonization to support this as the primary factor driving epidemiological differences in GBS disease [19] . Alternatively, there may be an underidentification of earlyonset cases in some study settings due to challenges in accessing healthcare, use of delivery practices promoting Gramnegative infections in some settings, or differences in microbiological techniques [36] .
GBS Case Ascertainment
The majority of studies relied on hospital-based case finding. This approach is likely to be optimal if the majority of births in the study population occur in a hospital, increasing the probability of rapid early onset case identification; the majority of infants return to the same hospital in a timely manner if they become ill after a postnatal discharge; and the hospital represents a specialist center to which infants in the study population born elsewhere are referred if presenting with a suspected serious infection.
The majority of GBS studies were based within tertiary neonatal referral centers, optimizing the potential for case finding. However, an underestimation of early-onset GBS cases remains possible if a significant proportion of the study population gives birth outside of the hospital, identifying GBS cases and access to healthcare is challenging and children therefore die before diagnosis. Only 2 studies commented on births occurring outside of the study hospital setting; in both cases, this represented a substantial proportion of the study population births [13, 14] . National health statistics reinforce this problem, as a substantial proportion of births in sub-Saharan Africa, India, and Bangladesh occur outside health institutions (42%-65%, 53%, and 85%, respectively) [37] . Alhough it is inappropriate to extrapolate national statistics to specific study populations, it remains of note that South Africa, reporting the highest incidence of GBS, also reports nationally a high proportion of hospital-based births (89%) [37] .
Darmstadt et al [16] attempted to increase case ascertainment by capturing births in the community. Unfortunately, of the 919 community assessments that resulted in a hospital referral recommendation, only 54% of referred patients complied within 2 days and compliance was lower in infants aged 0-6 days. Of the 259 neonatal deaths, 62% were never assessed by a health worker and 59% occurred within the first 2 days of life, consistent with the time period of greatest risk for the development of GBS neonatal sepsis [16] . The potential for case under-ascertainment therefore remains.
Culture Methodology
The methods of GBS isolation and identification (culture) are essential for accurate case identification. Higher GBS incidence estimates were consistently reported among studies using automated culture techniques, although this observation may be confounded by differences in the years of data collection, differences in funding, and therefore differences in the laboratory facilities available. Data on potential confounders that can increase false-negative culture rates [38] , including insufficient blood volume, the use of nonpediatric culture bottles resulting in diluted blood samples, and sample contaminants, were poorly reported across studies. However, the observed presence of coagulase-negative staphylococci in several studies [18, 29, 30] , usually only considered invasive pathogens when isolated in the blood of very low birth-weight infants with an e When comparing overall incidence of GBS, it should be noted that studies by Cutland et al [24] and Vaciloto et al [26] only captured EOD.
f Study recruited children aged <13 years with acute medical condition, but infants <60 days were included in analysis of sepsis. g For years 1987-89.
Causes of Variation in GBS Incidence
• CID 2012:55 (1 July) • 97 indwelling device, emphasizes the need for contamination rates to be better addressed in studies of severe neonatal infection. A comparison of GBS detection rates across studies would help determine whether automated methods are superior to manual methods. However, detection rates were only reported in 5 studies [12, 13, 22, 24, 28] , and interpretation was complicated by the use of different denominators across studies (eg, GBS detection among patients who were cultured, which did not always represent all patients with suspected disease).
Antibiotic Use
Intrapartum antibiotic prophylaxis use was rarely commented on, although 13 of 20 studies were completed prior to the end of the 1990s when the role of IAP is likely to have been limited. Broader antibiotic use could also potentially confound results: studies from South Africa and Kenya reported evidence of recent antibiotic usage in 10%-25% of the study population [14, 24] . There is a need to better quantify broad antibiotic use in the communities of interest and to further study its impact on GBS transmission and identification.
Limitations
Some limitations of review methodology may apply. Studies with incidence data but lacking sufficient methodological detail were excluded, and the conduct of many such studies in the remote past precluded requests for supplemental supportive information. Five literature databases were accessed to The study by Sigauque et al [15] is not presented in this table because neonatal disease was not stratified as EOD and LOD. However, the median age at presentation was 10 days after birth in this study (n = 31).
Abbreviations: EOD, early-onset disease; GBS, Group B Streptococcus; LOD, late-onset disease. a Not applicable because no cases of EOD were captured in the study. maximize study capture, but additional searching of the grey literature could potentially have yielded additional information. This review also has several strengths, including the application of inclusion and exclusion criteria that ensured a review based upon the most robust published data, independent review of GBS studies by 2 authors, and consideration of methodological parameters rarely discussed despite their potential to affect reported neonatal GBS incidence rates.
Conclusions
Despite the initial identification of approximately 15 000 citations, only 20 studies met all inclusion criteria with clear descriptions of case ascertainment, culture methodology, and incidence calculation. In eastern and southern Africa, GBS is a significant problem, as evidenced by a series of consistent reports in the literature with population-based incidence estimates. However, GBS data are lacking for large regions of Africa, Asia, and Latin America, and many existing reports represent data collected several decades ago. This review highlights the potential for reported GBS incidence to be confounded by several methodological parameters. A failure to diagnose cases in the community that fail to reach healthcare facilities, insufficient culture methods, and antibiotic usage may all lead to incidence underestimation. Unfortunately, a general lack of demographic data and detailed culture protocols precluded an accurate quantification of case under-ascertainment. Such issues may also extend to incidence estimates for other sepsis-causing organisms.
Few current data and methodological challenges within existing studies emphasize the need for prospective, populationbased GBS surveillance that uses adequate diagnostic tools and case-capture methodologies for community-born infants in developing countries (Supplementary Table 2 ). Accurate disease burden assessments are urgently needed, especially given recent advances in GBS vaccine development [39] and the proven concept of neonatal protection through maternal immunization [40] . Policy makers need to know the neonatal GBS disease burden to formulate effective prevention strategies that will support the objectives of the Millennium Development Goals.
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